Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)-Reference-Cited by-同舟云学术

Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)

Published:2017-07-31 Issue:9 Volume:15 Page:1834-1844
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Scipione C. A.¹²,McAiney J. T.³,Simard D. J.³,Bazzi Z. A.⁴,Gemin M.³,Romagnuolo R.⁵,Macrae F. L.⁶,Ariëns R. A.⁶,Hegele R. A.¹⁴⁷,Auld J.³,Gauld J. W.³,Boffa M. B.⁴,Koschinsky M. L.¹²

Affiliation:

1. Robarts Research Institute; London Ontario Canada

2. Department of Physiology & Pharmacology; Schulich School of Medicine & Dentistry; The University of Western Ontario; London Ontario Canada

3. Department of Chemistry & Biochemistry; University of Windsor; Windsor Ontario Canada

4. Department of Biochemistry; Schulich School of Medicine & Dentistry; The University of Western Ontario; London Ontario Canada

5. University Health Network; Toronto Ontario Canada

6. Thrombosis and Tissue Repair Group; Division of Cardiovascular and Diabetes Research; Leeds Institute of Cardiovascular and Metabolic Medicine; Faculty of Medicine and Health; University of Leeds; Leeds UK

7. Department of Medicine; Schulich School of Medicine & Dentistry; The University of Western Ontario; London Ontario Canada

Funder

Canadian Institutes of Health Research

Heart and Stroke Foundation of Canada

Natural Sciences and Engineering Research Council of Canada

Regeneron Pharmaceuticals

Pfizer, Inc.

Ionis Pharmaceuticals, Inc.

Amgen

Merck

Acasti

Abbott